Abstract
Dronedarone is a class III antiarrhythmic drug. Another class III drug, amiodarone, is currently the most commonly used antiarrhythmic drug for the maintenance of sinus rhythm in patients with atrial fibrillation (AF). However, its use is complicated by toxicities and complex dosing. Dronedarone is a structural derivative of amiodarone developed to provide a safer alternative. The efficacy of dronedarone has been demonstrated in patients with paroxysmal or persistent AF. A recent trial was conducted to determine whether these benefits extend to patients with permanent AF. This article will discuss the implications of this trial and the evolving role of dronedarone in the management of AF.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
